Cord blood stem cell therapy - Kangstem Biotech

Drug Profile

Cord blood stem cell therapy - Kangstem Biotech

Alternative Names: FURESTEM; FURESTEM-AD; FURESTEM-CD; FURESTEM-RA; hUCB-MSCs

Latest Information Update: 19 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kangstem Holdings
  • Developer Kangstem Biotech
  • Class Antirheumatics; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Atopic dermatitis; Crohn's disease
  • Phase I Rheumatoid arthritis
  • Discontinued Amyotrophic lateral sclerosis; Cancer; Diabetes mellitus; Niemann-Pick diseases; Pain; Psoriasis; Retinal disorders

Most Recent Events

  • 11 Nov 2016 Efficacy and adverse events data from a phase I trial for Rheumatoid arthritis were presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
  • 26 Oct 2016 Discontinued - Preclinical for Amyotrophic lateral sclerosis, Diabetes Mellitus, Cancer, Pain, Psoriasis, Retinal disorders, Niemann-Pick disease in South Korea (Parenteral)
  • 03 Oct 2016 Kang Stem Biotech plans a phase I trial for Plaque psoriasis in South Korea (NCT02918123)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top